前列地尔治疗高龄糖尿病合并慢性肾脏病患者的效果分析

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of Alprostadil in the treatment of elderly patients with diabetes and chronic kidney disease.Methods A total of 58 elderly patients with diabetes and chronic kidney disease treated in Changping Hospital in Dongguan City from October 25,2016 to October 25,2017 were selected as subjects.They were divided into control group and observation group according to the principle of random sampling,29 cases in each group.The patienys in control group were treated with conventional treatment,and the patients in observation group were given Alprostadil on basis of routine treatment.The clinical efficacy,serum creatinine(Cr),24 h urinary albumin excretion rate(24 h UAER),cystatin C,serum creatinine clearance rate (Ccr)levels and adverse reactions were compared between the two groups.Results After treatment,the Cr,24 h UAER and cystatin C in the observation group were lower than those in the control group,and the Ccr was higher than that in the control group,the differences were statistically significant(P＜0.05).The total effective rate of clinical treatment in the observation group was 93.1%,which was significantly higher than that in the control group(68.97%),and the difference was statistically significant(P＜0.05).There was no statistically significant difference in adverse reactions between the two groups(P＞0.05).Conclusion In clinic,elderly patients with diabetes and chronic kidney disease can be treated with a certain dose of Alprostadil at the same time of routine treatment,which can improve the clinical efficacy and quality of life.

Key words： Alprostadil Elderly Diabetes mellitus and chronic kidney disease

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PENG Xiang-hang
	CHEN Zhen-hua
	QIU Yu
	CHEN Xin-yu
	LIU Hui-dan

Cite this article:

PENG Xiang-hang,CHEN Zhen-hua,QIU Yu, et al. Analysis of the effect of Alprostadil in the treatment of elderly patients with diabetes and chronic kidney disease[J]. 中国当代医药, 2018, 25(14): 129-131.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I14/129

[1]	张万玲.前列地尔预防冠心病合并糖尿病患者PCI后对比剂肾病效果观察[J].山东医药，2015，55（38）：29-30.
[2]	Sagara M，Suzuki K，Aoki C，et al.Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease：a case-control study[J].Car Dia，2016，15（1）：1-10.
[3]	王珊珊，常宝成，单春艳，等.前列地尔序贯疗法治疗老年临床糖尿病肾病期患者的疗效观察[J].中华老年医学杂志，2014，33（2）：154-158.
[4]	Schneider C，Coll B，Jick SS，et al.Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus：a cohort study[J].Cli Epi，2016，8（1）：177-184.
[5]	王晓露，曾芙蓉，李凡.前列地尔联合贝前列素钠序贯治疗早期糖尿病肾脏病的临床观察[J].中国卫生标准管理，2015，6（29）：118-119.
[6]	双淑贞.前列地尔治疗高龄糖尿病并慢性肾脏病患者的疗效分析[J].当代医学，2016，22（32）：127-128.
[7]	周彩云.前列地尔治疗高龄糖尿病合并慢性肾脏病患者的疗效及安全性观察[J].中国民康医学，2016，28（19）：35-36.
[8]	李晨芳.前列地尔治疗高龄糖尿病并慢性肾脏病患者疗效分析[J].糖尿病新世界，2015，35（20）：7-9.
[9]	曲建娇，曲建慧.前列地尔治疗糖尿病足的现况[J].中国现代医生，2016，54（15）：164-168.
[10]	杨玲，孙利丽，陶思明.前列地尔治疗慢性肾脏病的临床疗效观察与分析[J].中国现代药物应用，2016，10（17）：26-27.
[11]	周瑞琴，李小巧，杨艳琴.前列地尔在高龄糖尿病合并慢性肾脏病治疗中的价值[J].医学新知杂志，2017，27（4）：406-407.
[12]	李银梅.前列地尔治疗高龄糖尿病合并慢性肾脏病的疗效及安全性评价[J].中国处方药，2016，14（11）：62-63.
[13]	罗锋.前列地尔治疗高龄糖尿病并慢性肾脏病患者疗效观察和安全性评价[J].航空航天医学杂志，2017，28（2）：214-215.
[14]	张振亚.前列地尔治疗高龄糖尿病并慢性肾脏病的疗效及安全性[J].中国组织工程研究，2015，19（B12）：92-94.
[15]	丁燕萍，王翼华.前列地尔治疗高龄糖尿病并慢性肾脏病患者疗效和安全性分析[J].黑龙江医药，2017，30（4）：798-799.
[16]	郭毅飞，李雪锋，李敏，等.血管紧张素原基因M235T多态性与糖尿病慢性肾脏疾病的相关性研究[J].临床和实验医学杂志，2016，15（21）：2081-2084.
[17]	邱双平，吴武忠.前列地尔联合还原型谷胱甘肽治疗慢性肾衰竭的临床研究[J].临床和实验医学杂志，2016，15（7）：654-656.
[18]	杨雪佳，孔立茶，刘少云，等.前列地尔对合并糖尿病的冠心病患者介入治疗中造影剂肾病的预防作用[J].临床和实验医学杂志，2018，17（3）：284-286.